{"id":11340,"date":"2019-11-27T04:56:04","date_gmt":"2019-11-27T04:56:04","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=11340"},"modified":"2022-07-29T07:09:09","modified_gmt":"2022-07-29T07:09:09","slug":"ptx-live-investor-briefing-26-november","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/","title":{"rendered":"PTX Live Investor Briefing &#8211; 26 November"},"content":{"rendered":"<p><iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/375823547?title=0&amp;byline=0&amp;portrait=0\" width=\"100%\" height=\"380\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":27262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-11340","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PTX Live Investor Briefing - 26 November - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PTX Live Investor Briefing - 26 November - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-27T04:56:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-29T07:09:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"enouvoteam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"enouvoteam\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/\"},\"author\":{\"name\":\"enouvoteam\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"headline\":\"PTX Live Investor Briefing &#8211; 26 November\",\"datePublished\":\"2019-11-27T04:56:04+00:00\",\"dateModified\":\"2022-07-29T07:09:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/\"},\"wordCount\":6,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/\",\"name\":\"PTX Live Investor Briefing - 26 November - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg\",\"datePublished\":\"2019-11-27T04:56:04+00:00\",\"dateModified\":\"2022-07-29T07:09:09+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PTX Live Investor Briefing &#8211; 26 November\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\",\"name\":\"enouvoteam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"caption\":\"enouvoteam\"},\"sameAs\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\"],\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PTX Live Investor Briefing - 26 November - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"PTX Live Investor Briefing - 26 November - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/","og_site_name":"PTX Therapeutics","article_published_time":"2019-11-27T04:56:04+00:00","article_modified_time":"2022-07-29T07:09:09+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg","type":"image\/jpeg"}],"author":"enouvoteam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"enouvoteam"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/"},"author":{"name":"enouvoteam","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"headline":"PTX Live Investor Briefing &#8211; 26 November","datePublished":"2019-11-27T04:56:04+00:00","dateModified":"2022-07-29T07:09:09+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/"},"wordCount":6,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/","name":"PTX Live Investor Briefing - 26 November - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg","datePublished":"2019-11-27T04:56:04+00:00","dateModified":"2022-07-29T07:09:09+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2019\/11\/PTX-Live-Investor-Briefing-26-November.jpeg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-live-investor-briefing-26-november\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"PTX Live Investor Briefing &#8211; 26 November"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c","name":"enouvoteam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","caption":"enouvoteam"},"sameAs":["https:\/\/template.reachmarkets.com.au\/investorportal"],"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/11340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=11340"}],"version-history":[{"count":1,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/11340\/revisions"}],"predecessor-version":[{"id":27263,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/11340\/revisions\/27263"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/27262"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=11340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=11340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=11340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}